Moderna's cancer vaccine cuts melanoma recurrence risk in early trial: What we know

A long-elusive dream may finally be within reach. Moderna's mRNA melanoma vaccine, intismeran, has shown promise in slowing the return of the skin cancer in trial patients — a sign that cancer vaccines could soon become a reality for millions.